

Trevi Therapeutics to Participate in Upcoming August Events

NEW HAVEN, Conn., Aug. 1, 2023 /PRNewswire/ -- [Trevi Therapeutics, Inc.](#) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in August.

BTIG Virtual Biotechnology Conference 2023

August 7-8, VIRTUAL

Fireside Chat: Tuesday, August 8th, 9:30 AM ET

Presenters: Jennifer Good, President and CEO, and Lisa Delfini, CFO

Stifel Biotech Executive Summit

August 14-16, Newport, RI

Fireside Chat: Wednesday, August 16th, 10:00 AM ET

Presenter: Jennifer Good, President and CEO

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis. Haduvio is a dual κ -opioid receptor agonist and μ -opioid receptor antagonist that works both centrally as well as peripherally in the lungs and has the potential for a synergistic anti-tussive effect to treat chronic cough.

The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant.

Parenteral nalbuphine is not scheduled by the US Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on [Twitter](#) and [LinkedIn](#).

Investor Contact

Katie McManus

Trevi Therapeutics, Inc.

203-304-2499

k.mcmanus@trevitherapeutics.com

Media Contact

Rosalia Scampoli

914-815-1465

rscampoli@marketcompr.com

SOURCE Trevi Therapeutics, Inc.

<https://ir.trevitherapeutics.com/2023-08-01-Trevi-Therapeutics-to-Participate-in-Upcoming-August-Events>